Stay updated on Safety & Efficacy of Filgotinib & Lanraplenib in LMN Clinical Trial

Sign up to get notified when there's something new on the Safety & Efficacy of Filgotinib & Lanraplenib in LMN Clinical Trial page.
Latest website image capture
Clouds background image

Latest updates to the Safety & Efficacy of Filgotinib & Lanraplenib in LMN Clinical Trial page

  1. Check
    4 days ago
    Change Detected
    Summary
    The page displays the ClinicalTrials.gov record for a completed Phase 2 study of filgotinib and lanraplenib for lupus membranous nephropathy, including eligibility criteria, study design, outcomes, and results-related documents.
    Difference
    54%
    Check dated 2026-11-08T13:30:25.000Z thumbnail image
  2. Check
    11 days ago
    Change Detected
    Summary
    The site revision label changed from v3.7.2 to v3.8.0 while the page continued to display a 403 Forbidden error.
    Difference
    0.2%
    Check dated 2026-11-01T14:38:04.000Z thumbnail image
  3. Check
    18 days ago
    Change Detected
    Summary
    A sitewide notice announces updates to NIH websites and says the agency is transitioning from the term “Artificial Intelligence” to “Super Intelligence” in some content.
    Difference
    1%
    Check dated 2026-10-25T13:56:12.000Z thumbnail image
  4. Check
    25 days ago
    Change Detected
    Summary
    The footer revision identifier changed from v3.7.1 to v3.7.2, while the page continues to display a 403 error.
    Difference
    0.2%
    Check dated 2026-10-18T14:15:28.000Z thumbnail image
  5. Check
    32 days ago
    Change Detected
    Summary
    The revision identifier in the footer changes from v3.7.0 to v3.7.1 on the ClinicalTrials.gov 403 Forbidden page.
    Difference
    0.2%
    Check dated 2026-10-11T13:24:50.000Z thumbnail image
  6. Check
    53 days ago
    Change Detected
    Summary
    The page now shows a 403 Forbidden error, indicating access to the study record is blocked. This reflects an access issue rather than an update to the study details.
    Difference
    19%
    Check dated 2026-09-20T19:44:14.000Z thumbnail image

Stay in the know with updates to Safety & Efficacy of Filgotinib & Lanraplenib in LMN Clinical Trial

Enter your email address, and we'll notify you when there's something new on the Safety & Efficacy of Filgotinib & Lanraplenib in LMN Clinical Trial page.